Systemic administration of interleukin‐2 inhibits inflammatory neutrophil migration: role of nitric oxide
Open Access
- 1 August 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 148 (8) , 1060-1066
Abstract
1 Interleukin‐2 (IL‐2) has proinflammatory properties that limit its therapeutic use. Its side effects are mainly explained by the induction of a vascular leakage syndrome. Cytokines, as TNF‐α and IL‐1β, and nitric oxide (NO) generated by IL‐2‐activated leukocytes play a role in this defect. 2 As the systemic release of these mediators inhibits neutrophil migration to a specific inflammatory site, we investigated now whether IL‐2 administrated systemically inhibits the neutrophil recruitment to the inflamed peritoneum. The involvement of NO in the process was also addressed. 3 Using peritoneal neutrophils, we show that the intravenous treatment of the mice with IL‐2 inhibits the neutrophil migration induced by carrageenin, LPS or fMLP. In confirmation, IL‐2‐treated mice showed a significant reduction in leukocyte rolling and adhesion in mesenteric microcirculation evaluated after carrageenin, LPS and fMLP injections. Aminoguanidine prevented the inhibitory effect of IL‐2 on carrageenin‐induced neutrophil migration, rolling and adhesion. In contrast, IL‐2 failed to reduce the lung leukocyte infiltration induced by LPS. Therefore, IL‐2 inhibition of neutrophil migration is organ specific. 4 Our results indicate that IL‐2 administered systemically inhibits neutrophil recruitment to some inflammatory sites through a mechanism dependent on NO. The results also reinforce the needs to determine the mechanism by which patients treated with IL‐2 show increased risks of infection. British Journal of Pharmacology (2006) 148, 1060–1066. doi:10.1038/sj.bjp.0706835Keywords
This publication has 53 references indexed in Scilit:
- Immune cell migration in inflammation: present and future therapeutic targetsNature Immunology, 2005
- TNF-α promotes a stop signal that inhibits neutrophil polarization and migration via a p38 MAPK pathwayJournal of Leukocyte Biology, 2005
- Inhibition of Leukocyte Rolling by Nitric Oxide during Sepsis Leads to Reduced Migration of Active Microbicidal NeutrophilsInfection and Immunity, 2002
- Effects of inhibition of PDE4 and TNF‐α on local and remote injuries following ischaemia and reperfusion injuryBritish Journal of Pharmacology, 2001
- Rapid Effect of Interleukin?2 Therapy in Human Immunodeficiency Virus–Infected Patients whose CD4 Cell Counts Increase Only Slightly in Response to Combined Antiretroviral TreatmentThe Journal of Infectious Diseases, 2001
- Interleukin-2 in the treatment of malignant melanomaExpert Opinion on Investigational Drugs, 1998
- Interleukin 2 and its receptors: recent advances and new immunological functionsImmunology Today, 1996
- Effects ofNG-Nitro-L-arginine Methyl Ester, an Inhibitor of Nitric Oxide Synthesis, on IL-2-Induced LAK Cell Generationin Vivoandin Vitroin Healthy and Tumor-Bearing MiceCellular Immunology, 1996
- Interleukin-2 increases the oxidative activity and induces migration of murine polymorphonuclear leukocytes in vivoInternational Journal of Immunopharmacology, 1990
- Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.Journal of Experimental Medicine, 1989